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INTRODUCTION 
 
The human immune system has developed intricate mechanisms to protect the body by 
discriminating between infectious agents and self. Unfortunately, in some cases these 
mechanisms can be bypassed and immune responses may be elicited by antigens derived 
from self. The loss of tolerance to autoantigens may lead to the development of autoimmune 
diseases.  
 
Autoimmune diseases are chronic inflammatory diseases of unknown etiology where both 
genetic and environmental factors play a role. Human leukocyte antigens (HLA) have been 
shown to be the most important susceptibility factor for several of the autoimmune diseases, 
what strongly suggests the involvement of T cells. In many autoimmune diseases the self 
antigen causing the disease is not known. This is the case for rheumatoid arthritis, multiple 
sclerosis and type 1 diabetes. For celiac disease however, the trigger of the disease is known 
to be gluten. Interestingly, although gluten was known to be the environmental factor for 
years, it was not until a decade ago that a posttranslational modification of gluten mediated by 
an enzyme called tissue transglutaminase 2 (TG2) was discovered to be critical for the 
disease. The posttranslationally modified gluten peptides bind the disease associated HLA-
molecules with a higher affinity than the unmodified gluten peptides, what results in a 
multifaceted T-cell response. Thus, posttranslational modifications of self-antigens, or in this 
case; of food antigens normally tolerated by the body, is one way in which novel epitopes are 
created that are not tolerated by the immune system. Interestingly, immune responses 
directed towards enzymatically modified self-antigens were also reported for other 
autoimmune diseases, e.g. against citrullinated proteins in rheumatoid arthritis and 
methylated and phosphorylated proteins in systemic lupus erythematosus. As the importance 
of posttranslational modifications of gluten peptides is acknowledged in celiac disease, further 
research in this field may be relevant also for other autoimmune diseases. 
 
In this thesis, we have used mass spectrometry-based strategies to investigate the 
posttranslational gluten modifications catalyzed by the transglutaminase enzymes implicated 
in gluten sensitive diseases. The main focus has been on TG2 and its important role in T-cell 
epitope selection in celiac disease. 
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Transglutaminases 
The enzyme family of transglutaminases 
Transglutaminases (TGs: EC 2.3.2.13) are a family of structurally and functionally related 
enzymes expressed in almost all mammalian cells and tissues. The major function of the TGs 
is to covalently crosslink proteins through an acyl-transfer reaction between a 
peptidylglutamine and a polypeptide-bound lysine. These crosslinks are highly stable and are 
resistant to mechanical and proteolytic breakdown. Numerous biological processes are 
dependent on the crosslinking activity of TGs, ranging from wound healing and apoptosis to 
extracellular matrix assembly.  
 
Nine TG genes have been identified in human, where eight of them encode active enzymes 
(TG1-TG7 and plasma factor XIII) [1]. The TG genes are closely related and five of the TGs 
are found within two gene clusters; TG5, TG7 and Band 4.2 cluster on chromosome 15q15, 
while TG3 and TG6 cluster at 20p13. Notably, TG2 is also localized at chromosome 20, but at 
20q11.23. There is a high degree of similarity between the TG enzymes, both in their primary 
sequence, protein structure and regarding their catalytic mechanism. It has been suggested 
that the TG genes derive from a common ancestral gene related to cysteine proteases [2]. 
 
Among the eight active TGs only five posses a clear biological function (Table 1). Although 
each of the TGs has its own distinct targets for crosslinking and their own typical tissue 
distribution, they are often found in combination with each other. The enzymatic activity of the 
TGs is tightly regulated throughout the body, both by various cofactors and through their 
localization, to prevent excessive protein aggregation.  
 
Table 1. The human transglutaminase family 
Protein Gene   Mw (kDa) Tissue expression a Localization Function 
Factor  
XIIIa b 
F13A1 83 
Platelets, astrocytes, dermal 
dendritic cells, chondrocytes, 
placenta, plasma, synovial fluid 
Cytosolic, 
extracellular 
Blood 
coagulation [3], 
bone growth [4] 
TG1 TGM1 90 Keratinocytes, brain Membrane, cytosolic Cell-envelope formation [5] 
TG2 TGM2 80 Ubiquitous 
Cytosolic, nuclear, 
membrane, cell 
surface, extracellular 
Multiple (see 
text) [6] 
TG3 c TGM3 77 Squamous epithelium, brain Cytosolic Cell-envelope formation [5] 
TG4 TGM4 77 Prostate Unknown 
Semen 
coagulation in 
rodents [7] 
TG5 TGM5 81 Ubiquitous except for the CNS 
and lymphatic system Unknown Unknown 
TG6 TGM6 ? Unknown Unknown Unknown 
TG7 TGM7 ? Ubiquitous 
 Unknown Unknown 
Band 4.2 d EPB42 72 Red blood cells, bone marrow, 
fetal liver and spleen Membrane 
Membrane 
skeletal 
component [8] 
a Only tissues of high level expression are indicated.  b Thrombin activated. c Protease activated. d No TG activity. 
Table 1 is modified from [9]. 
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Transglutaminase 2 
Transglutaminase 2 (TG2) was the first TG to be discovered over 40 years ago [10]. Since 
then it has been extensively studied and it is now the best characterized enzyme in the family. 
Still, the precise physiological functions of TG2 remain to be elucidated. 
 
Structure and conformation 
TG2 is comprised of four distinct domains; a N-terminal -sandwich harboring a fibronectin 
binding site, a catalytic core containing the active site, and two C-terminal -barrel domains 
[11]. The conformation and the enzymatic activity of TG2 is regulated by the small ligands 
GTP and Ca2+ [12]. When Ca2+ is present and GTP is absent, TG2 is in its catalytically active 
form. Binding of GTP induces a conformational change that stabilizes the enzyme in a more 
compact, catalytically inactive form [13]. Two crystal structures of TG2 have recently been 
reported, one describing TG2 in a closed, GDP bound conformation [14], and the other 
describing it in an open, extended confirmation where the active site is occupied by a peptide-
like inhibitor [15]. To date, the structure of the Ca2+ bound form of TG2 is unresolved. 
 
Enzymatic activity  
TG2, in common with most TGs, has a cysteine proteinase-like active site where a catalytic 
triad is involved in the crosslinking reaction [16]. The catalytic triad is comprised of cysteine 
277, histidine 335 and aspartic acid 358. In the presence of Ca2+, cysteine 277 performs a 
nucleophilic attack on the -carbon of the glutamine side chain of an acyl-donor substrate, 
resulting in a thioester bound enzyme-substrate intermediate and release of ammonia. Next, 
a nucleophilic primary amine (small biogenic amines or the -amine group of a lysine; acting 
as acyl-acceptor) or water attacks the enzyme-substrate complex and the enzyme, together 
with the transamidated or deamidated product, are released. TG2 can also exert isopeptidase 
activity [17] by hydrolyzing the transamidated products. This reaction also results in the 
generation of deamidated products.  
 
Substrate specificity  
The only amino acid that can act as an acyl-donor substrate for TG2 is glutamine. The 
sequence specificity of TG2 towards acyl-donor substrates has in the recent years been 
thoroughly investigated and was found to be strongly influenced by the primary sequence. In 
particular the positioning of proline residues (P) plays a crucial role. Vader et al. and 
Fleckenstein et al. examined the targeting of glutamine residues (Q) in peptides by guinea pig 
TG2, addressing the deamidation and transamidation reaction, respectively [18;19]. 
Glutamine residues in the QXP sequence motif were found to be targeted by TG2, while 
glutamine residues with a P in position +1 or +3 were not targeted. Other amino acids in 
positions -1, +1, +2 and +3 were found to influence the targeting to a lower extent. The same 
QXP sequence motif was later confirmed in studies using phage-display peptide libraries and 
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human TG2 [20;21]. Targeting of glutamine residues within intact proteins will in addition be 
influenced by the protein’s secondary and tertiary structure. 
 
A variety of compounds can serve as acyl-acceptor substrates for TG2. These are primary 
amines like present in the side chain of the amino acid lysine or small biogenic amines such 
as histamine. TG2 is much less selective towards lysine residues than towards glutamine 
residues, but the enzymatic reactivity will be affected by the amino acids preceding the lysine 
residue. While a leucine, serine, alanine or arginine residue has been shown to enhance the 
reactivity, a proline or glycine residue reduces the reactivity [22;23]. 
 
Expression and localization 
TG2 is ubiquitously expressed in many different cells and tissues. In addition it can be up-
regulated during wound healing and in response to stress signals [24;25]. The enzyme is 
mainly localized in the cytosol (80%) [9], but it has also been detected in the nucleus [26], 
mitochondria [27;28], at the cell surface [29] and in the extracellular matrix (ECM) [30]. The 
presence of TG2 in the ECM and on the cell surface is, however, a conundrum as TG2 lacks 
both stabilizing disulfide bonds and a leader sequence required to traverse from the cytosol 
over the plasma membrane. Secreted TG2 either localizes to the cell surface or is deposited 
in the ECM.  
 
An enzyme with multiple functions  
TG2 is a multifunctional enzyme which serves various biochemical functions depending on its 
subcellular location (Figure 1). In the cytosol, the concentration of GTP is high (200-500 μM) 
while the Ca2+ concentration is low (<1 μM). TG2 will therefore mainly be catalytically inactive 
and the enzyme can function as a G-protein. Acting as a G-protein, TG2 transmits signals 
from several kinds of cell surface receptors including membrane -1B and 1D- andrenergic 
receptors [31;32], TP thromboxane A2 receptor [32] and the oxytocin receptor [33], leading 
to activation of the downstream cytoplasmic target phospholipase C and inositol trisphosphate 
(IP3) production, which in turn results in an increased cytoplasmic Ca2+ concentration. 
Notably, TG2 has also been shown to exert protein disulfide isomerase activity in the cytosol 
[34]. During inflammation and apoptosis the intracellular Ca2+ level will rise and TG2 may be 
activated to exert its crosslinking activity [35]. 
 
In the ECM the Ca2+ concentration is sufficiently high for constitutive activation of TG2 (2.5-5 
mM) [36], thus it is primarily believed to act as a crosslinking enzyme. However, a recent 
study reported that the majority of extracellular TG2 is inactive under normal conditions but 
transiently activated upon tissue injury [37]. TG2 in the extracellular space is directly involved 
in the assembly, remodeling and stabilization of the ECM in different tissues [35] in addition to 
wound healing and angiogenesis [38].  
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On the cell surface, TG2 associates with integrins and via its tight interaction with fibronectin it 
is involved in cell adhesion, cell spreading and cell migration [2;39-42]. It has also been 
demonstrated that cell surface TG2, when acting as a integrin co-receptor, is able to transmit 
signals from the extracellular to the intracellular compartment through the activation of the 
Rhoa/ROCK and the focal adhesion kinase signaling pathway [43]. Notably, the interaction of 
TG2 with integrins does not require crosslinking activity. Despite the high Ca2+ concentration 
in the extracellular space, it is unclear whether cell surface TG2 is active or whether it is held 
latent due to the massive associations with integrins. 
 
 
 
Figure 1. Biochemical activities of TG2. In the presence of Ca2+, TG2 catalyzes acyl-transfer 
reactions between specific protein-bound glutamines and either primary amines or the amino-group of 
selected protein-bound lysine residues. Water can replace the primary amine what results in 
deamidation of the targeted glutamine residue. TG2 can also exert isopeptide bond hydrolysis and 
indirectly deamidate its substrate. On the cell surface, TG2 acts as an integrin co-receptor which binds 
tightly to fibronectin and thereby promotes cell-matrix interactions. In the cytosol, TG2 exerts its function 
as a GTPase and transmits signals from seven-transmembrane helix receptors activating phospholipase 
C (PLC1). Figure modified from [11] 
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TG2 in human diseases 
TG2 has been implicated in the pathogenesis of various human diseases including celiac 
disease [44], cancer [45;46] and the neurological diseases Alzheimer’s and Huntington’s [47]. 
The functional role of the enzyme in the diseases is, however, often unknown. Only in celiac 
disease is the main function of TG2 well established.  
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Celiac disease 
Clinical aspects 
Celiac disease (CD) is a genetically-determined, chronic inflammatory disorder caused by the 
ingestion of gluten proteins in wheat and similar proteins from barley and rye. The disease is 
characterized by small intestinal damage with loss of absorptive villi, hyperplasia of the crypts 
and a massive infiltration of lymphocytes in the epithelium and in the lamina propria [48]. 
Clinical symptoms include diarrhea, anemia, osteoporosis, depression and infertility in 
addition to skin manifestations and neurological diseases [49]. Elimination of gluten from the 
diet leads to clinical improvement in most patients. CD is a frequent disorder, affecting about 
1:100 in populations of mainly Caucasians [50;51]. Patients on a gluten-containing diet have 
increased levels of serum antibodies to both gluten and the enzyme TG2 [44]. These 
antibodies are strictly dependent on the intake of gluten. Serological tests for IgA anti-TG2 
antibodies are used for the diagnosis of CD due to their high sensitivity and specificity (>98%) 
[52]. The final diagnosis of CD is still to be based on the finding of characteristic changes in 
the histology of small intestinal biopsies.  
 
Genetic factors 
CD displays a strong genetic association. The concordance rate is around 8% in first-degree 
relatives and about 75% in monozygotic twins [53]. The HLA genes are the key genetic risk 
factors in CD, and they are believed to account for about 50% of the genetic contribution [54]. 
More than 90% of CD patients express the HLA-DQ2.5 (DQA1*05/DQB1*02) molecule, while 
the majority of the remaining patients display the HLA-DQ8 (DQA1*03/DQB1*0302) molecule 
[55]. However, in the normal population the prevalence of HLA-DQ2 is as high as 25-30%, 
what suggests additional non-HLA susceptibility genes involved in CD pathogenesis. In the 
recent years several non-HLA candidate genes have been identified through genome-wide 
association studies [56-58]. Although the contribution of these genes is minimal compared to 
the HLA genes, they point towards a functional role in the immune system. 
 
Gluten – the trigger of celiac disease 
Gluten, the major storage protein in wheat, was identified as the trigger of CD more than 50 
years ago [59]. Subsequent studies revealed that also rye, barley and possibly oat provoke 
the disease [60-62], although the toxicity of the latter is debated. 
 
Wheat gluten contain hundreds of protein components that are present either as monomers 
or as oligo- and polymers when linked by interchain disulfide bonds [63]. The molecular 
weights of the proteins range from around 30.000 to more than 10 million [64]. Traditionally, 
gluten proteins are classified into two main groups according to their solubility in aqueous 
alcohol; the ethanol-soluble gliadins and the ethanol-insoluble glutenins. The gliadins are 
mainly monomeric proteins and they have traditionally been further separated into --, - 
and 	-gliadins according to their electrophoretic behavior [65]. Later studies on amino acid 
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sequences, however, revealed that the - and - gliadins belong to one group (/-type) [64]. 
The ethanol-insoluble glutenins, which comprise aggregated proteins, become soluble in 
aqueous alcohol after reduction of the disulfide bonds and the glutenin subunits can be 
divided into low molecular weight (LMW) and high molecular weight (HMW) glutenins. The 
amino acid composition of gluten is unique, with a high content of both glutamine (30%) and 
proline residues (10%) and with very few charged residues. Characteristic for both gliadins 
and glutenins are their repetitive sequence motifs rich in glutamine (Q), proline (P), 
phenylalanine (F) and tyrosine (Y). The repetitive motifs of the gliadins are typically 
QPQPFPQQPYP (-gliadin), QPQQPFP (-gliadin) and PQQPFPQQ (	-gliadin) while the 
LMW glutenins typically contain repetitive units such as QQQPPFS [64]. As proline residues 
enforce strong restraints on the conformation of a peptide chain, the gluten peptides will often 
form a polyproline type II helix [66]. 
 
Similar alcohol-soluble fractions have been demonstrated in barley (hordeins) and rye 
(secalins) [67;68]. For cereals in general, the alcohol soluble fraction is termed prolamines 
and the alcohol insoluble fraction is termed glutelins [69]. Notably, the prolamines of barley 
and rye are rich in glutamine- and proline residues, while the nontoxic prolamines of rice and 
corn have a lower glutamine and proline content. Most T cells isolated from gluten challenged 
small intestinal biopsies of CD patients recognize the gliadin fraction of gluten [70]. 
 
Peptide binding to HLA-DQ2/DQ8 
Gluten peptides are recognized by gluten-reactive T cells only in the context of HLA-DQ2.5 or 
-DQ8 molecules [70;71]. These HLA-molecules seem to be uniquely suited for presentation of 
gluten-derived peptides. The peptide binding motif of HLA-DQ2.5 has been thoroughly 
investigated and it was found to be rather different from those of other HLA class II molecules. 
HLA-DQ2.5 can, in contrast to other HLA-molecules, accommodate peptides with several 
proline residues. In addition, a preference for negative charged anchor residues has been 
found in positions P4, P6 and P7 of the peptide binding motif [72-74]. This preference for 
binding negatively charged residues is shared by HLA-DQ8, where it is found for the anchor 
residues in positions P1 and in P9 [75;76].   
 
The gluten specific immune response 
In CD there is a well-established adaptive immune response towards specific gluten peptides. 
The high amount of proline residues in gluten makes it relatively resistant to degradation by 
luminal and brush-border enzymes [77]. Fragments of gluten will therefore survive digestion 
and can be transported across the mucosal epithelium as polypeptides. Several mechanisms 
have been suggested to explain this peptide transport from the intestinal lumen into the 
lamina propria [78-80]. The enzyme TG2, which is present in the small-intestinal mucosa, will 
mediate an ordered deamidation of specific glutamine residues within the proteolytically 
stable peptides. Importantly, the affinity of the gluten peptides to the disease associated HLA-
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molecules is strongly enhanced by the negative charges introduced by deamidation. Upon 
recognition of the HLA-peptide complex by HLA-DQ2.5- or HLA-DQ8 restricted gluten 
reactive CD4+ T cells, a cytokine response dominated by interferon- is induced [81]. Several 
gluten T-cell epitopes and their deamidation sites have been identified during the recent years 
[82-90]. 
 
It was recently reported that gluten in addition can induce an innate immune response. The 
“toxic” -gliadin derived peptide p31-43 can increase the production of IL-15 resulting in the 
expression of NKG2D receptors on intraepithelial T cells and its ligand MICA on epithelial 
cells. The subsequent NKG2D-MICA interaction may result in destruction of the intestinal 
epithelium[91].  
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The role of transglutaminase 2 in celiac disease 
TG2-mediated deamidation and transamidation of gluten peptides 
TG2 plays an important role in the adaptive immune response in CD by deamidating the 
gluten peptides and thereby increasing their binding affinity to HLA-DQ2.5 and HLA-DQ8. 
Notably, deamidation by TG2 is also expected to slow down the off-rate so that the gluten 
peptide will stay on the HLA molecule for a longer period of time [92]. TG2 can target specific 
glutamine residues within the gluten peptides and catalyze either a deamidation or a 
transamidation reaction. Deamidation results in conversion of a glutamine residue to a 
negatively charged glutamic acid residue, whereas in the transamidation reaction primary 
amines are crosslinked to the side chain of a glutamine residue (Figure 2).  
 
The in vivo deamidation of gliadin peptides in CD is not completely understood. TG2 
expression has been demonstrated mainly in the brush border and in the subepithelial region 
in the small intestine [93] where the presence of primary amines would favor the 
transamidation reaction. However, as most gut T cells recognize the gluten peptides 
preferentially or only after being deamidated by TG2 [94], deamidation of gluten peptides 
obviously occurs in vivo. The ratio between transamidation and deamidation has been shown 
to be dependent on the concentration of amines and peptides present, and also on the pH in 
the environment [19]. At a lower pH (<6.5), the deamidation reaction is favored suggesting 
that deamidation may occur in compartments of the gut with slightly acidic pH. To date, it is 
not known where TG2 processes gluten peptides in the intestinal mucosa. 
 
 
Figure 2. TG2-catalyzed deamidation and transamidation of gluten peptides. In the presence of 
Ca2+, the TG2 active site cysteine reacts with specific glutamine residue side chains within the gluten 
peptides. An intermediate TG2-substrate complex is formed and ammonia is released. A primary amine 
or water attacks the TG2 substrate complex displacing the enzyme and generating a transamidated or 
deamidated gluten peptide, respectively. TG2 can further hydrolyze the transamidated peptide to a 
deamidated peptide. Figure is modified from [95]. 
 16
Autoantibodies to TG2 
TG2 was identified as the autoantigen in CD in 1997 by Dieterich et al., and the TG2-specific 
antibodies now represent a hallmark of the disease. These antibodies are found in the small 
intestine where they have been shown to co-localize with extracellular TG2 [96] and in the 
blood where they are used as diagnostic tools for CD [97]. Notably, the presence of these IgA 
and IgG antibodies strongly depends on the dietary intake of gluten. A hypothesis based on a 
hapten-carrier model has been proposed to explain the presence of the antibodies in the 
celiac lesion [98]. Uptake of TG2-gluten complexes by TG2-specific B cells is suggested to 
result in activation of CD4+ gluten-reactive T cells which will give the necessary help to the B 
cell for isotype switching and secretion of TG2-specific antibodies. Gluten peptides have been 
demonstrated to be crosslinked to TG2 either by a transient thioester bond to the active site 
cysteine [99], or to specific lysine residues of the enzyme via very stable isopeptide bonds 
[100]. As it to date is not known where the formation and the cleavage of such complexes 
take place, the hapten-carrier hypothesis remains to be proven. 
 
Whether the anti-TG2 autoantibodies have a functional role or not in the pathogenesis of CD 
is conversely discussed. Several groups have investigated whether the autoantibodies have 
an effect on the activity of TG2 but contradictory results have been reported [101-103]  
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The role of other transglutaminases in gluten sensitive diseases 
Gluten sensitive diseases (GSD) are a collection of diseases that are induced by dietary 
gluten and they typically present as CD. However, manifestations can also exist in the 
absence of the gastrointestinal symptoms typically observed in patients with CD, such as in 
the skin disease dermatitis herpetiformis (DH) and in the neurological disorder gluten ataxia 
(GA). Interestingly, other TGs than TG2 appear to be the main autoantigen in these diseases. 
 
DH is affecting around 10% of patients with CD [104]. The disease is characterized by sub-
epidermal blistering and deposition of IgA antibodies in the papillary dermis, and the 
symptoms usually disappear when gluten is removed from the diet. The antibody profile of DH 
is similar to that observed in CD patients. However, in addition to the circulating antibodies to 
TG2, DH patients have specific antibodies towards another TG isoform, TG3 (epidermal TG). 
IgA deposits in the dermal papillae have been shown to co-localize with TG3, but not with 
TG2 [105]. 
 
GA is a newly recognized neurological condition and it is one of the more frequent neurologic 
syndromes associated with CD. Most of the patients have no gastrointestinal symptoms.  The 
clinical manifestations of GA are primarily in the brain or in the peripheral nervous system, 
and the disease is believed to be caused by antibody damage to Purkinje cells in the 
cerebellum. Thus, removal of gluten from the diet may not improve the symptoms as damage 
to the cerebellum may be permanent. The majority of the GA patients have circulating 
antibodies towards TG2. In addition, they have antibodies recognizing the novel TG isoform 
TG6 [106]. Post mortem examination of brain tissue showed that TG6 was present in IgA 
deposits in the cerebellum. 
 
It is not clear whether TG3 and TG6 are expressed in the intestine. However, the antibody 
production which is dependent on gluten and the IgA isotype of the antibodies suggest an 
intestinal origin. 
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Mass spectrometry and proteomics in celiac disease research 
In the last decade, the technological developments in mass spectrometry (MS) have 
expanded rapidly with continuous improvements in sensitivity, resolution and obtained mass 
accuracy. This progress has been taken advantage of to address many biochemical, 
enzymatic and immunological questions related to the pathogenesis of CD. MS has been 
applied to characterize natural ligands of HLA-DQ2 [107], to identify antigens recognized by 
serum antibodies of CD patients [108] or to characterize gluten proteins. The major 
achievements regarding our current understanding of the pathogenesis of CD have however 
been made in the three following fields. 
 
Specificity and enzymatic activity of TG2 
MS has been important for the characterization of the specificity of TG2. Two proteomic 
approaches have been used to study the influence of the primary sequence on the TG2-
mediated targeting of specific glutamine residues. Fleckenstein et al. incubated synthetic 
peptide libraries with TG2 in the presence of primary amines and semi-quantified the 
transamidated peptides using MS [19]. The targeting by TG2 was found to be strongly 
influenced by the positioning of proline residues. These results were similar to findings by 
Vader et al. who analyzed deamidation within synthetic substitution analogs of gliadin 
peptides using MS [18].  
 
In order to evaluate the proposed hapten-carrier hypothesis, complexes of TG2 and gliadin 
peptides were characterized using biochemical and mass spectrometric analysis. The TG2-
gliadin complexes were found to be formed either by relatively unstable thioester bonds 
during catalysis, or via very stable isopeptide bonds between the gluten peptides and 
particular lysine residues of the enzyme. Mass spectrometric analysis of tryptic digests of the 
complexes revealed six acyl-acceptor lysine residues within TG2 [100]. 
 
Identification of T-cell epitopes in gluten 
The first gluten T-cell epitopes were identified in 1998 by the groups of Sollid et al. and 
Koning et al. [83;109]. With the rapid progress in MS, several HLA-DQ2.5 and HLA-DQ8 
restricted T-cell epitopes were identified in the following years [82-90]. The T-cell epitopes 
have been identified from gluten digests of various complexities; e.g. from single 
recombinant- or -gliadin proteins [85;86] or from purified subgroups of gluten containing 
either -gliadin, -gliadin or glutenin proteins [87]. The peptide digests were fractionated 
followed by testing in T-cell assays. Fractions containing T-cell stimulatory peptides were 
analyzed by MS, and identified peptides were synthesized, treated with TG2 and again tested 
in T-cell assays to identify the T-cell stimulatory peptides. The deamidation sites were 
identified by tandem MS. 
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Mass spectrometry to study gluten proteolysis 
In order for a gluten peptide to be a T-cell epitope it must survive proteolytic digestion in the 
gut. Shan et al. analyzed proteolytic digests of recombinant 
-gliadin to identify regions with 
high proteolytic stability using liquid chromatography coupled to mass spectrometry (LC-MS). 
They discovered a 33mer peptide  that  was stable to all gastric, pancreatic and brush-border 
enzymes [77]. TG2-treatment of this peptide followed by mass spectrometric analysis 
revealed that the peptide was an excellent substrate for TG2. Interestingly, the 33mer peptide 
contained multiple copies of the already identified -gliadin epitopes and it was found to be 
efficiently recognized by T cells from all CD patients [110]. Similarly, a proteolytically stable 
26mer from a recombinant -gliadin was identified which is a good substrate for TG2 and 
harbors several known -gliadin epitopes [111]. With the aim to degrade these proteolytically 
stable gluten fragments, Shan et al. treated gluten with peptidases capable of cleaving 
proline-rich peptides. LC-MS based methods were central in the assessment of degradation 
of the immunostimulatory peptides. 
 
In the last decade, MS has been instrumental also in the characterization of cereal proteins. 
MS-based studies have made a significant contribution to the understanding of the 
composition and structure of the gluten proteins and for determining their molecular mass 
(rewieved in [112;113]). 
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AIMS OF THE STUDY 
 
The focus of this thesis has been to investigate the role of TG2 in the generation of gluten T-
cell epitopes in CD. Two MS-based methods were established for this purpose; a method to 
determine the kinetics of TG2-mediated deamidation of gluten peptides and a proteomic 
method to identify the best substrates of TG2 in complex digests of whole gluten. The 
quantification method was in addition applied to investigate whether other TG isoforms than 
TG2 could accommodate gluten peptides as substrates. 
 
The specific aims of my thesis were: 
 
 To quantify TG2-mediated deamidation of the known HLA-DQ2.5 restricted gliadin 
epitopes and see whether this correlates with the frequency by which the epitopes are 
recognized by T cells of CD patients.  
 
 To investigate whether the TG isoforms TG3 and TG6 that are implicated in the gluten 
sensitive diseases DH and GA, respectively, can utilize gluten peptides as substrates and 
whether they can form covalent complexes with the gluten peptides. 
 
 To identify the preferred peptide substrates of TG2 in proteolytic digests of whole gluten 
and address whether these peptides are identical to the known gluten T cell epitopes. 
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SUMMARY OF PAPERS 
 
Paper I  
In this study we established a quantitative, MS-based approach to address the kinetics of 
TG2-mediated deamidation of different HLA-DQ2.5 restricted gliadin epitopes. Our results 
demonstrated that there are large differences in the rate of deamidation for the different 
peptides. We observed a positive correlation between how quickly the various epitopes 
becomes deamidated by TG2 and the frequency by which the epitopes are recognized by T 
cells of CD patients. In addition, we found that TG2 deamidates the individual glutamine 
residues within the gluten epitopes with very different rates, what may influence whether the 
epitopes are better recognized in the context of HLA-DQ2.5 or HLA-DQ8.  
 
Paper II 
The TG isoforms TG3 and TG6 are considered to be the main autoantigens in the gluten 
sensitive disorders DH and GA, respectively. We investigated whether these enzymes can 
accommodate gluten peptides as substrates what may be relevant for the gluten-dependent 
autoantibody production. Our results show that similar to TG2, TG3 and TG6 can specifically 
deamidate gluten T-cell epitopes, but the enzymes differ in their fine specificities. We found 
that both TG3 and TG6 were able to form complexes with gluten peptides through thioester 
linkage although less efficiently than TG2. Only TG6 was found to generate isopeptide linked 
complexes. These findings support the notion that TG3 and TG6 are involved in the gluten 
induced autoimmune responses of DH and GA. 
 
Paper III  
This study aimed to identify the preferred peptide substrates of TG2 in a highly 
heterogeneous proteolytic digest of whole gluten. We established a method for enrichment of 
gluten peptides targeted by TG2 and identified these substrates by LC-MS/MS, database 
searching of a tailored gluten database and manual data interpretation. Interestingly, our 
results revealed that the majority of the identified preferred substrates of TG2 harbor known 
gluten T-cell epitopes, and moreover, we identified two novel T-cell epitopes by this approach. 
Our findings demonstrate that the selective forces exerted by TG2, together with those 
created by gastrointestinal proteolysis, are key factors to determine the repertoire of gluten 
epitopes in CD.  
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METHODOLOGICAL CONSIDERATIONS 
 
Production of recombinant human TG2 
Recombinant human TG2 was expressed in BL21 competent E.coli with an N-terminal hexa-
histidine tag and purified as described by Piper et al. [99]. The His6-TG2 plasmid was a kind 
gift from Chaitan Khosla, Stanford University. The yield and the activity of the batch of 
recombinant TG2 used in this thesis were found to be similar to those of previously produced 
batches of TG2. The deamidation activity was assessed by MS by measuring the deamidation 
of a gluten epitope peptide at different concentration and at different time points. 
 
Quantification of peptide deamidation by mass spectrometry 
The conventional method of quantifying TG2-mediated peptide deamidation is via a coupled 
assay established previously by others [114]. In this assay, the ammonium released in the 
TG2-catalyzed reaction serves as a substrate in a subsequent reaction catalyzed by 
glutamate dehydrogenase. This reaction consumes NADH which is photometrically 
monitored. However, as only the sum of the ammonium production is measured in this assay, 
it is not possible to determine the deamidation of each of the peptides when present together 
in a peptide mixture. Capillary electrophoresis combined with laser induced fluorescence-
detection has in addition been used to measure deamidation of gluten peptides [19]. Although 
this method is highly sensitive, it also shows limitations when it comes to measuring of 
peptides in a mixture. MS, on the other hand, allows a simultaneous and quantitative analysis 
of deamidation for each peptide present in a mixture. In addition, the deamidation of individual 
glutamine residues within an individual peptide can be quantified by MS. Another advantage 
of the MS-based method is that it is fast and only small amounts of peptide and enzyme are 
required. 
 
The conversion of a glutamine (Mw 128.1) to a glutamic acid residue (Mw 129.1) in a peptide 
results in a mass increase of +1 Dalton. Thus, the isotopic envelopes of the native and the 
deamidated peptides overlap. Quantification of deamidation is consequently based on 
determination of the centroid mass using the formula mc = mi Ii / Ii (mc: centroid mass, mi: 
masses of individual signals in the isotopic envelope, Ii: intensity of the individual signals in 
the isotopic envelope) [115]. To quantify the total deamidation of a TG2-treated peptide, the 
calculated centroid mass of the native peptide was subtracted from the calculated centroid 
mass of the TG2-treated peptide giving a centroid mass shift which corresponds to the 
average number of deamidation (Figure 3). Importantly, the mass spectrometric response for 
the native and the deamidated peptide was first demonstrated to be equal, what is a 
prerequisite for the method applied.  
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Figure 3. Quantification of TG2-mediated peptide deamidation. The centroid mass of the native 
peptide (upper panel) and the TG2-treated, deamidated peptide (lower panel) is calculated by the given 
formula mc = mi Ii / Ii (mc: centroid mass, mi: masses of individual signals in the isotopic envelope, Ii: 
intensity of the individual signals in the isotopic envelope). The calculated centroid mass of the native 
peptide is subsequently subtracted from the calculated centroid mass of the TG2-treated peptide what 
gives the total deamidation of the TG2-treated peptide (here shown as 1 Dalton e.g. corresponding to 
complete deamidation of a peptide in which only one glutamine residue is targeted). 
 
Total deamidation of the peptides was measured by MALDI-TOF MS (matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry). To quantify deamidation of individual 
glutamine residues within the peptides, centroid masses of fragments reporting on specific 
glutamine residues were calculated. Due to its better resolution, those MS/MS experiments 
were performed on a Q-TOF (quadrupole-time-of-flight) instrument. 
 
Enrichment of TG2 peptide substrates from a digest of whole gluten 
Wheat gluten digested with PTCEC (pepsin, trypsin, chymotrypsin, elastase and 
carboxypeptidase) yields an extremely complex mixture of peptides and tens of thousands of 
different peptides may be present in the final digest. In order to identify substrate peptides of 
TG2 from such a complex mixture, a method for enrichment of these substrates is needed. 
We established an approach which is based on the transamidation reaction catalyzed by 
TG2. To selectively label and enrich the peptides targeted by TG2, a biotinylated primary 
amine; 5-biotinamido-pentylamine (5-BP), was used. TG2 covalently crosslinks 5-BP to 
distinct glutamine residues in the gluten peptide substrates what will increase the mass of the 
peptides by 311.17 Dalton per incorporation. The transamidated and hence biotinylated 
peptides were enriched from the digest using magnetic streptavidin beads. Enriched gluten 
peptides were eluted off the beads by adding an excess of biotin. 
 
To ensure that only the best substrates among the gluten peptides would become 
transamidated, small amounts of 5-BP and short incubation times with TG2 were chosen. 
+1 Da
I1 
I2 
I3 
I4 
m1 m2 m3 m4 
mC(t0) 
mC(t1) 
m1 x I1 + m2 x I2 + ….. + mn x In 
I1 + I2 + ….. + In 
Average number of deamidation  
= mC(t1) - mC(t0) 
mC = 
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These conditions are probably not reflecting the in vivo situation where primary amines likely 
are present in ample amounts and the concentration of TG2 is the limiting factor. However, in 
both cases TG2-mediated reaction takes place in a competitive environment suggesting that 
the best peptide substrates of TG2 identified by our approach are also targeted by TG2 in 
vivo.  
 
Identification of enriched TG2 peptide substrates by LC-MS 
The enriched TG2 peptide substrates were analyzed by both a nano-LC Q-TOF mass 
spectrometer and a nano-LC LTQ-Orbitrap mass spectrometer. A database consisting of all 
known sequences of common wheat (Triticum aestivum) was constructed using the 
Sequence Retrieval System (SRS) at the European Bioinformatics Institute. The obtained LC-
MS/MS (liquid chromatography/tandem-mass spectrometry) data were searched against the 
Triticum aestivum database. Transamidation by 5-BP was implemented in the in-house 
Mascot search engine as a modification of glutamine residues and was selected as a variable 
modification together with deamidation (NQ) and pyro-glutamate formation (N-terminal Q). All 
reported hits were manually interpreted to validate the identification. This was especially 
important considering the very similar sequences of the different gluten proteins present in the 
wheat gluten digest. In addition, to resemble the in vivo digestion, we used a mixture of 
different enzymes, PTCEC, with different cleavage specificities (trypsin, cleavage after K, R; 
elastase, cleavage after A, G, S, V; chymotrypsin, not very specific, prefers to cleave at F, W, 
Y, M, L; pepsin, broader specificity, reported to be similar to that of chymotrypsin; 
carboxypeptidase A, non-specific, prefers aromatic and long side-chain amino acids [111]). 
Thus, for database searching we selected “none” in the enzyme settings. 
 
T-cell proliferation assay 
T-cell recognition of synthetic gluten derived peptides was tested using a 3H-thymidine 
incorporation assay. T-cell proliferation is measured upon recognition of the peptide-HLA 
complex by the T-cell receptor, where irradiated HLA-DQ2.5 homozygous EBV-transformed B 
lymphoblastoid cells are used as antigen presenting cells. A high correlation between T-cell 
proliferation and other effector functions has been reported [81]. It should however be noted 
that the method gives a bias towards T cells that proliferates well upon activation which 
means that gluten specific T cells with a poorer proliferation could be neglected.   
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GENERAL DISCUSSION 
Selection of gluten T-cell epitopes in celiac disease 
Wheat gluten is an extremely complex mixture of proteins. Only a few of the thousands of 
peptides generated by gastrointestinal digestion of gluten proteins serve as T-cell epitopes. 
Several factors are influencing what gluten peptides are eventually presented to the gluten-
specific T cells; proteolytic stability of the peptides, their ability to be a TG2 substrate and their 
affinity to HLA-DQ2.5 and/or HLA-DQ8. Importantly, these factors are acting together. 
 
Proteolytic stability of epitopes 
Resistance to gastrointestinal proteolysis is a prerequisite for a gluten peptide to be selected 
as a T-cell epitope. The high amount of proline residues in gluten will affect its susceptibility to 
digestion as only a limited number of mammalian proteases are able to cleave the amide 
bond N-terminally of proline residues [66]. Interestingly, it was previously discovered that the 
gliadin-derived T-cell epitopes were not randomly spread in gliadin but rather clustered in 
regions rich in proline residues [86].  
 
A proteolytically stable -gliadin derived 33mer peptide that contains several copies of the 
known -gliadin epitopes is considered to be the immunodominant peptide in CD. Similarly, a 
-gliadin derived proteolytically stable 26mer peptide that harbors several known -gliadin 
epitopes has been identified. This suggests the existence of also other potential immunogenic 
proteolytically resistant peptides in gluten. Shan et al. thus performed a computational 
prediction of all peptides generated from wheat, rye and barley when digested with the major 
pancreatic enzymes. Their results revealed that long, proteolytically stable peptides existed in 
all of these cereals [111]. However, 50% of the identified peptides did not contain any of the 
known T-cell epitopes suggesting that the T-cell epitope repertoire in gluten has not yet been 
thoroughly mapped or that other factors than proteolytic stability play a role in the selection of 
epitopes.  
 
Selection of epitopes by TG2 
The epitopes require deamidation by TG2 to increase their binding affinity to HLA-DQ2.5 or 
HLA-DQ8. The high frequency of proline residues in the epitopes not only prevents intestinal 
proteolysis but also plays a crucial role regarding the specificity of TG2 as the positioning of 
the proline residues determines whether a glutamine residue is targeted or not.  
 
To date, several TG2-dependent T-cell epitopes have been identified. The majority of these 
derive from the - and -gliadins and they are restricted to HLA-DQ2.5. Notably, a few TG2-
independent gluten epitopes have been reported [87;116]. Interestingly, it seems as the 
epitopes show a hierarchy in their recognition by patient derived T cells. While the -gliadin 
epitopes in general are recognized by T cells from almost all patients, the -gliadin epitopes 
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are infrequently recognized. This hierarchy could be explained by the rates by which TG2 
deamidates the different epitopes. In paper I we addressed this hypothesis and we 
demonstrated large variations in the rate of deamidation of the different known HLA-DQ2.5 
restricted epitopes. We found that the -gliadin epitopes in general were faster deamidated 
by TG2 than the -gliadin epitopes. Our results thus suggest that there is a correlation 
between the level of deamidation and the frequency of gluten epitope specific T cells 
observed in patient biopsies.  
 
Two studies have aimed to identify the peptide substrates of TG2 in the gliadin fraction of 
gluten [117;118]. However, these studies were carried out with purified gliadin or with 
recombinant -gliadin. So far, no studies have aimed to identify the peptide substrates of TG2 
in whole wheat gluten, probably due to its extreme complexity. Considering the abundance of 
proline and glutamine residues in gluten, one would expect the presence of numerous 
potential substrates of TG2. Results in paper I did however show that the velocity by which 
TG2 deamidates the different epitope peptides differs significantly. It may thus be that in vivo 
only a limited number of gluten peptides will be substrates of TG2. In paper III we developed 
a method to enrich and identify the preferred substrates of TG2 under the competitive 
conditions which exist when a highly complex digest of whole wheat gluten is applied. 
Strikingly, we found that the majority of the best peptide substrates of TG2 harbored complete 
or partial sequences of T-cell epitopes. Thus, after enzymatic gluten degradation TG2 is not 
active on a broad scale of different gluten peptides but shows a high preference for those that 
carry T-cell epitopes.  
 
Results from paper III also demonstrated the important role of proteolytic stability in the 
selection of T-cell epitopes. Those T-cell epitopes for which we observed only partial 
sequences in the identified favored TG2 substrates are known to be infrequently recognized 
by T cells from CD patients. In contrast, the epitopes that were observed with their complete 
9mer core region are frequently recognized by T cells of CD patients. Thus, the hierarchy of 
T-cell responses observed among the patients is clearly affected by both gastrointestinal 
proteolysis and deamidation by TG2. 
 
TG2-mediated deamidation in vivo 
Although we and several other groups have put much emphasis in investigating the TG2-
catalyzed deamidation of gluten peptides, it is still not clear where and when the gluten 
peptides encounter active TG2 in vivo and thus become deamidated. TG2 is mainly 
expressed in the subepithelial region of the mucosa and to a lesser extent in the brush border 
[93]. In the subepithelial region the pH is neutral and ample amounts of primary amines are 
likely to be present. Although the transamidation reaction most likely is the favored reaction in 
this environment, deamidation has been shown to occur in the presence of primary amines 
[19]. The deamidation reaction has however been demonstrated to significantly increase 
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when the pH is lowered [19]. In the proximal small intestine the pH is around 6.6 [119]. One 
may therefore envisage that TG2 encounters the gluten peptides in the brush border where 
deamidation could be the favored reaction. It has also been suggested that TG2 is 
endocytosed and remains active in the early endosomes where there is sufficient Ca2+ [19]. 
Integrin associated TG2 could thus be implicated in receptor-mediated endocytosis of gluten 
peptides. Another possibility is that gluten complexed to surface immunoglobulin on TG2-
specific B cells (hapten-carrier hypothesis) is endocytosed and subsequently becomes 
deamidated, either by direct deamidation by TG2 or indirectly by isopeptide bond hydrolysis of 
the TG2-gluten complex.  
 
Peptide binding to HLA-DQ2.5 and HLA-DQ8 
The final determinant in the selection of gluten epitopes is peptide binding to HLA-DQ2 or 
HLA-DQ8 (Figure 4). In order to generate a T-cell response the deamidated gluten peptides 
must have a sufficient binding affinity to these HLA-molecules. Both the positioning of proline 
residues and the positioning of the deamidated glutamine residues will affect this binding 
affinity. Previously it was shown that some gliadin epitopes were recognized by T cells in the 
context of HLA-DQ2.5 or HLA-DQ8 when bound in exactly the same register, but they 
required different glutamine residues to be deamidated [89]. This finding was supported in 
paper I. We found that TG2 deamidated the individual glutamine residues within the epitopes 
with very different efficiencies and thus generated epitopes with a HLA-DQ2.5 or HLA-DQ8 
signature. This “deamidation pattern” appears to determine whether some epitopes are better 
recognized in the context of HLA-DQ2.5 or HLA-DQ8.  
 
 
 
Figure 4. Selection of gluten T-cell epitopes. Gluten peptides that are rich in proline residues (P) will 
survive intestinal degradation. TG2 can deamidate specific glutamine residues (Q) within these 
proteolytically stable peptides and the positioning of deamidated glutamine residues and proline 
residues will affect the peptides’ binding affinity to HLA-DQ2.5. Figure modified from [120]. 
 
In conclusion, our results shed light on the crucial role of TG2 in epitope selection in CD. It 
may be tempting to speculate whether other TGs play a similarly important role in the epitope 
selection of gluten sensitive diseases other than celiac disease. 
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Gluten sensitive diseases and redundancy of transglutaminases  
Other TGs than TG2 seem to be implicated in the gluten sensitive diseases DH and GA. The 
main autoantigens in DH and GA are now considered to be TG3 and TG6, respectively. In 
addition to specific antibodies towards these autoantigens, both DH and GA patients have 
antibody populations recognizing TG2 and antibodies which are cross-reactive with TG2 and 
TG3/TG6. The production of autoantibodies to TG3, and most likely also to TG6, is dependent 
on gluten intake. This may suggest that TG3 and TG6, similarly to TG2, are able to create 
hapten-carrier complexes thereby driving their own antibody production. In paper II we 
wanted to shed light on the enzymes’ potential redundancy in gluten sensitive diseases by 
comparing the biochemical properties of these closely related enzymes using gluten peptides 
as model substrates. We showed that gluten peptides indeed are substrates for TG3 and 
TG6. Both enzymes were found to form thioester linked complexes with the peptides, 
although to less extent than TG2. However, in an in vivo setting the capability of TG3 and 
TG6 to create complexes with gluten may be of importance. A prerequisite for an involvement 
of TG3 and TG6 in these gluten sensitive diseases is of course that TG3 and TG6 will 
encounter gluten peptides. Preliminary results by D. Aeschlimann (personal communication) 
indicate that the enzymes are expressed in the intestine. 
 
Surprisingly, it was reported that TG2 knock-out mice have no clear spontaneous 
abnormalities [121;122]. It has therefore been speculated whether the activity of other TGs 
could compensate for the lack of TG2. In fact, other TGs including TG3 have been reported to 
be upregulated in TG2 knock-out mice [1]. The hypothesis of redundancy is further 
strengthened by our results, demonstrating that different TG isoforms can perform similar 
tasks.  
 
Notably, TG3 and TG6 may display a stronger sequence preference towards other gluten 
peptides than the TG2-dependent gluten T-cell epitopes tested in this paper. An interesting 
approach would thus be to use the methodology established in paper III to identify the best 
gluten peptide substrates of TG3 and TG6.  
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Future therapeutic strategies of celiac disease 
At present, the only treatment of CD is a life-long exclusion of gluten from the diet. As gluten 
is present in various food products total elimination is both difficult and inconvenient and 
quality of life is reduced for many patients. Alternative therapies are thus highly desired. 
However, it is relatively safe to be on a gluten-free diet what must be taken into account when 
developing novel therapies. With respect to the selection process of gluten T-cell epitopes, 
several interesting targets can be considered. Our results have underlined the crucial role of 
TG2 in that selection what suggests that therapeutic approaches based on the inhibition of 
TG2 could be beneficial for CD patients.  
TG2-based therapeutic strategies  
Two ex vivo studies have demonstrated the potential of TG2 inhibitors as therapeutic agents 
for CD. Both Molberg et al. [94] and Maiuri et al. [123] showed that inhibition of endogenous 
TG2 in small intestinal biopsies from CD patients with cystamine and 2-[(2-
oxopropyl)thio]imidazolium inhibitor L682777, respectively, could prevent gluten peptide 
deamidation and consequently led to reduced T-cell activation.  
 
To date, a variety of potential inhibitors of the active site of TG2 have been developed. They 
can be divided into competitive amine inhibitors, reversible inhibitors and irreversible inhibitors 
depending on their inhibition mechanism [95]. The best characterized TG2 inhibitors are 
competitive amine inhibitors such as putrescine, cystamine, spermidine, histidine, 
monodansylcadaverine and 5-(biotinamido)pentylamine [95]. These compounds are 
commercially available, chemically stable and non-toxic (exception: cystamine) [124;125]. 
Competitive amine inhibitors inhibit TG2 activity by competing with poly-peptide bound lysine 
residues and other primary amines in the transamidation reaction, thus TG2-mediated 
transamidation may continue to occur in the presence of these inhibitors. In vivo however, 
these compounds should not be considered as selective for TG2 [126]. Reversible inhibitors 
block the access of substrates to the active site without covalently modifying the enzyme. 
Among the reversible inhibitors are the cofactors GTP and GDP which will close the active 
confirmation of TG2 and the metal ion Zn2+ which competes for the same site as Ca2+ in the 
enzyme [127-129]. Irreversible TG2 inhibitors covalently modify cysteine 277 in the active site 
of the enzyme. The irreversible inhibitors 3-halo-4,5-dihydroisoxazoles are one of the most 
studied classes. KCC009, a synthetic compound containing halo-dihydroisoxazole is 
particularly promising. It has been demonstrated to inhibit intestinal TG2 when given orally 
and it shows low toxicity in mice. The compound in addition has a short serum half-life what 
limits its exposure to other organs [130]. A main drawback of these compounds are however 
their low solubility in buffers at physiological pH [95]. 
 
Since TG2 is a multifunctional enzyme involved in numerous biological processes, its 
systemic inhibition can be damaging. Although TG2 knock-out mice have no obvious 
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abnormalities they seem to have a systemic triggering of apoptosis [131]. Hence, the activity 
of any potential TG2 inhibitor should be restricted to the gut. An optimal TG2 inhibitor should 
in addition fulfill other criteria including low toxicity, high proteolytic stability and good 
solubility. Importantly, the inhibitor should be metabolized in the liver to avoid systemic effects 
in the body. To minimize possible side effects of unspecific inhibition on other TGs, isoform 
specific inhibitors will be required.  
 
TG2-mediated deamidation of gluten peptides is assumed to occur extracellularly in the gut 
mucosa. A potential danger of inhibiting extracellular TG2 is therefore to impair TG2’s activity 
with respect to e.g. tissue formation and wound healing. However, as proteins of the ECM are 
excellent substrates of TG2, one may envisage that inhibition of most of the TG2 present in 
the ECM mainly would affect the generation of deamidated gluten peptides. An appealing 
strategy would be to develop TG2 inhibitors capable of selectively inhibit the deamidation 
reaction what would limit potential side-effects as the transamidation reaction would not be 
affected. 
 
Alternative therapeutic approaches 
Degradation or removal of T-cell epitopes 
Enzymatic degradation of gluten is also considered as an attractive strategy for oral therapy. 
To date, several prolyl endopeptidases (PEPs) capable of cleaving proline-rich gluten 
peptides are studied for their potential use either alone or in combination with a glutamine 
specific endoprotease [132-136]. Both in vitro and in vivo (rat) experimental systems have 
been developed in order to address the kinetics of gluten degradation by PEPs and the 
minimal therapeutic dose required. The efficiency of oral therapy is however questionable as 
a high amount of PEP and prolonged exposure seems to be needed to completely break 
down all immunogenic gluten peptides. Ongoing clinical trials will show the therapeutic 
potential of oral enzyme supplementation. 
 
Another enzymatic therapeutic strategy was suggested by Gianfrani et al. where 
transamidation of wheat flour using microbial TG and lysine or lysine methyl ester as amines 
was shown to abolish the stimulatory capacity of gliadin [137]. Recently, a clinical trial was 
reported in which treated CD patients were tested for their tolerance to transamidated wheat 
flour. Approximately half of the patients were found to be tolerant [138]. 
 
An alternative approach would be to remove or lower the level of epitopes in wheat gluten. 
This could potentially be achieved by developing non-toxic wheat strains through traditional 
breeding or by genetic engineering of wheat. However, the number and repetition of the 
epitope peptides in wheat makes this approach very difficult and it may also have a negative 
influence on the baking quality of those wheat strains. In any case, a comprehensive 
characterization of the immunogenic peptides in all gluten proteins is first required. 
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Blocking of peptide presentation by HLA-DQ molecules 
Another apparent approach for therapy would be to block HLA-DQ2 or HLA-DQ8 presentation 
of gluten peptides to CD4+ T cells. Notably, peptide blockers are expected to have few side 
effects as most individuals are heterozygous for HLA molecules. Several studies have aimed 
to develop suitable peptide blockers based on proteolytically stable gluten peptide analogues 
[139-141]. As gluten peptides bind to HLA-DQ2 with a mediocre affinity, the bottleneck hereby 
is to generate binders with sufficiently high affinity. Recently, Jüse et al. identified several 
high-affinity HLA-DQ2 binders using soluble peptide libraries and recombinant soluble HLA-
DQ2 molecules as screening tools [142]. The best peptide ligand, FWADYEEEW, bound 50-
fold better than the immunodominant gluten epitope DQ2--I-gliadin. However, in contrast to 
gluten peptides most other peptides will be degraded by gastrointestinal enzymes in vivo. 
Thus, further attempts to stabilize such peptide lead structures towards proteolysis, e.g. by 
amidation of the C-terminus and acetylation of the N-terminus, or by including non-natural 
amino acids, are required to make this approach successful. 
 
Peptide-based therapy 
Many of the drugs which are currently under development as therapeutic agents for CD are 
thought to be a supplement to the gluten free diet. Peptide-based therapeutic vaccines on the 
other hand would greatly improve the quality of life for patients as such a vaccine has the 
potential to give a long-term qualitative change in the immune response to gluten. The aim is 
to recover the immunological tolerance to gluten by feeding the patients with deamidated 
gluten peptides in multiple low doses. The key to create an effective peptide-based therapy is 
therefore to identify the hierarchy of immunogenicity of gluten peptides. This is a big 
challenge as the intestinal T-cell responses to gluten seem to be very heterogeneous [90]. 
The gliadin proteins of gluten are considered to be the most immunogenic and several studies 
have compared the T-cell responses among HLA-DQ2.5 positive patients towards different 
gliadin epitopes. Considering the high sequence similarity between the proteins in gluten one 
would expect the presence of several immunogenic peptides also in the glutenin fraction. The 
TG2-modified T-cell stimulatory gliadin and glutenin peptides identified from whole wheat 
gluten in our study (paper III) could thus be potential candidates for a peptide-based therapy.  
 
Interestingly, peptide-based vaccines can induce immune tolerance not only to the selected 
immunodominant epitopes, the tolerance may potentially also spread to other less dominant 
immunogenic epitopes [143]. A peptide-based vaccine, “Nexvax2”, developed by the 
company Nexpep with Dr. Robert Anderson in the lead, is currently in a clinical trial in 
Australia (www.clinicaltrial.org). 
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Mass spectrometry-based strategies and applications in future therapy 
In the last couple of years, specific detection of individual peptides present in highly 
heterogeneous samples by multiple reaction monitoring (MRM) has made huge progress. 
This technology, when performed on triple quadrupole mass spectrometers is highly sensitive 
and allows for quantification of selected peptides in complex mixtures down to attomole 
amounts [144]. MRM is thus well suited for the targeted detection of any given gluten peptide 
in gluten-free food. Gluten-free food is traditionally validated by several commercial enzyme-
linked immunosorbent assay (ELISA) kits [145]. These are based on different monoclonal or 
polyclonal antibodies generated against a variety of gliadin components. Proteomic methods 
using LC-MS/MS aiming to qualitatively and quantitatively detect traces of gluten in gluten-
free food have in addition been developed [146] where gliadin-components common for 
several wheat varieties have then been selected as protein markers. The large set of epitopes 
identified to date allows searching specifically for the presence of these immunogenic epitope 
peptides in gluten using MRM. The first studies have now taken this into account. Sealey-
Voyksner et al. selected six potential immunogenic gluten peptides that ionize well in the 
mass spectrometer as markers for gluten content in food. A highly specific and sensitive 
analytical LC-MS/MS method using MRM was then developed for quantification of these 
gluten peptides in various food and consumer products [147].  
 
In addition, MRM may be useful in the development of other therapeutic strategies. Wheat 
strains engineered to have a low level of immunogenicity or wheat where the gluten epitopes 
have been “masked” could similarly be analyzed by LC-MS/MS using MRM to ensure the 
complete removal of the epitopes. MRM may also be used to specifically monitor degradation 
of specific epitope peptides in cereals treated with different PEPs. Of course MRM will only 
detect the gluten peptides specified to be targeted by that approach, meaning that a 
comprehensive characterization of all epitopes in gluten proteins is required to take full 
advantage of that analytical technique. The epitope peptides identified in paper III may thus 
be taken into account when selecting peptides for targeted MRM detection. The MS-based 
method established in our study may also be an interesting approach to identify TG2-
dependent epitopes in other cereals immunogenic for CD patients.  
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FINAL COMMENTS 
This thesis has aimed to investigate TG catalyzed modifications of gluten peptides in order to 
understand the enzyme’s role in the pathogenesis of gluten sensitive diseases. The “missing 
link” between TG2’s affinity for the different gluten peptides and the observed hierarchy in 
gluten T-cell responses in CD patients has been established and a potential redundancy 
among the TGs implicated in gluten sensitive diseases has been demonstrated. 
The best substrates of TG2 identified from complex gluten digest by the established MS-
based method were found to mainly harbor the known T-cell epitopes. Hence, the method 
functioned as a rapid screening method to identify TG2-dependent T-cell epitopes. As only a 
very few epitopes have been identified from other cereals toxic for CD patients, the 
established enrichment method could further be applied to proteolytic digests of rye and 
barley with the aim to identify novel T-cell epitopes. The method may potentially also be used 
to identify the best substrates of other TGs. The finding that TG3 and TG6 similarly to TG2 
can accommodate gluten peptides implies that also these TG isoforms can drive their own 
antibody production and may also play a role in T-cell epitope selection in the gluten sensitive 
diseases DH and GA. The enrichment method could thus be utilized to analyze the selection 
of gluten peptides by TG3 and TG6. 
In general, the results presented in this thesis demonstrate the crucial role of enzymes in 
generating posttranslationally modified antigens which are recognized by T cells. This 
suggests that enzymatic modifications of self-proteins could be a more general mechanism in 
which T-cell epitopes are created. Future research should shed light on whether other 
enzymes play a similarly crucial role as TG2 in the pathogenesis of other autoimmune 
diseases. 
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Abstract 
Background: Celiac disease is a T-cell mediated chronic inflammatory disorder of the gut 
that is induced by dietary exposure to gluten proteins. CD4+ T cells of the intestinal lesion 
recognize gluten peptides in the context of HLA-DQ2.5 or HLA-DQ8 and the gluten derived 
peptides become better T-cell antigens after deamidation catalyzed by the enzyme 
transglutaminase 2 (TG2). In this study we aimed to identify the preferred peptide substrates 
of TG2 in a heterogeneous proteolytic digest of whole wheat gluten.  
Methods: A method was established to enrich for preferred TG2 substrates in a complex 
gluten peptide mixture by tagging with 5-biotinamido-pentylamine. Tagged peptides were 
isolated and then identified by nano-liquid chromatography online-coupled to tandem mass 
spectrometry, database searching and final manual data validation. 
Results: We identified 31 different peptides as preferred substrates of TG2. Strikingly, the 
majority of these peptides were harboring known gluten T-cell epitopes. In addition, two TG2 
peptide substrates were predicted to bind to HLA-DQ2.5 but did not contain previously 
characterized sequences of T-cell epitopes. Both these peptides elicited T-cell responses 
when tested for recognition by intestinal T-cell lines of celiac disease patients, and they thus 
contain novel T-cell epitopes. We also found that the intact 9mer core sequences of the 
respective epitopes were not present in all peptide substrates. Interestingly, those epitopes 
that were represented by intact forms were frequently recognized by T cells in celiac disease 
patients, whereas those that were present in truncated versions were infrequently recognized. 
Conclusion: TG2 as well as gastrointestinal proteolysis play important roles in the selection 
of gluten T-cell epitopes in celiac disease.  
 
 
 
Introduction 
Celiac disease is an intestinal chronic inflammatory disorder elicited by dietary wheat gluten 
and related proteins from barley and rye. The disease is characterized by malabsorption, 
flattening of mucosa and the presence of autoantibodies. The large majority of the celiac 
disease patients express the HLA-DQ2.5 and/or HLA-DQ8 molecules [1], and gluten specific 
T-cells restricted to these HLA-molecules can be isolated from intestinal biopsies of the 
patients [2,3]. The peptide binding motifs of HLA-DQ2.5 and HLA-DQ8 have been thoroughly 
investigated and both molecules show a preference for negative charges at certain anchor 
positions; DQ2.5 in positions P4, P6 and P7 [4-6] and DQ8 in positions P1 and P9 [7,8]. 
Interestingly, these restricted T cells recognize gluten peptides only or preferentially after they 
undergo deamidation, a modification which is catalyzed by the enzyme transglutaminase 2 
(TG2). 
 
TG2 is a calcium-dependent enzyme which targets specific glutamine residues in peptides 
and proteins for either transamidation (crosslinking) or deamidation [9]. In the transamidation 
reaction, a stable isopeptide bond is formed between a peptidylglutamine residue (acyl-donor) 
and the amino group of an acyl-acceptor, e.g. peptidyllysine or a primary amine molecule. 
Deamidation of the targeted glutamine residue results in conversion to a glutamic acid and 
introduces a negative charge. It has been demonstrated that both for the deamidation [10] 
and transamidation reactions [11] the targeting of glutamine (Q) residues in peptides is 
strongly influenced by the positioning of C-terminally located proline (P) residues. Whereas a 
Q residue in the QXP consensus sequence is targeted by TG2, Q residues in a QP or QXXP 
sequence motif are not.  
 
During the recent years several T-cell epitopes of wheat gluten have been identified [12-19]. 
The majority of these epitopes derive from the gliadin protein fraction of gluten and is 
presented to T cells in the context of HLA-DQ2.5. Notably, the gliadin epitopes often cluster in 
regions rich in proline residues. Conceivably, the selection of the T-cell epitopes is governed 
by several factors. T-cell epitopes are usually longer than 9 amino acids, and protection 
against complete digestion in the gastrointestinal tract imposed by proline residues seems 
important [20]. Further, a selective force is exerted by TG2 as these epitopes are dependent 
on deamidation by this enzyme. Finally, epitope selection by HLA seems of importance as 
both HLA-DQ2.5 and HLA-DQ8 prefer binding of peptides with negatively charged anchor 
residues. Importantly, all these selective forces will act in concert.  
 
Several recent studies have pointed towards a role of TG2 in the selection of T-cell epitopes 
in celiac disease. Using a set of synthetic overlapping peptides covering the whole sequence 
of a -gliadin protein, those peptides that were quickly deamidated by TG2 were also 
recognized by T-cell lines of celiac disease patients [11]. We have also demonstrated that the 
known HLA-DQ2.5-restricted gliadin epitopes are substrates for TG2, but the rate by which 
this modification occurs differs considerably between the peptides [21]. We found a 
correlation between the rate of deamidation of the different epitopes and their T cell 
immunostimulatory capacity. Finally, the finding that proline governs the specificity of the 
enzyme and that gluten T-cell epitopes are rich in proline residues further supports the notion 
of a selective force exerted by TG2.  
 
In this study we aimed to shed further light on the role of TG2 in the selection of gluten T-cell 
epitopes. Gluten is an extreme complex mixture of diverse proteins. Several hundred distinct 
gluten proteins are belonging to the gliadin and glutenin fractions of a single wheat variety, 
and therefore tens of thousands different peptides will be present in a digest of wheat flour. 
To mimic the selection of T-cell epitopes from this vast sea of peptides that is present in the 
gut after gluten ingestion, we have developed a method to identify the preferred peptide 
substrates for TG2 in a proteolytic digest of whole gluten. Interestingly, we found that the 
great majority of preferred substrates for TG2 from this heterogeneous mixture are indeed 
peptides that harbor known gluten T-cell epitopes. 
Materials and Methods 
Synthesis of peptides and purification of recombinant human TG2 
Synthetic peptides were purchased from GL Biochem Ltd (Shanghai, China). Recombinant 
human TG2 was expressed in Escherichia coli with an N-terminal hexa-histidine tag and 
purified as described previously [22] with some minor modifications [23]. 
 
Proteolysis of gluten 
Whole gluten (Bob’s Red Mill, Milwaukie, Oregon) digested with pepsin, trypsin, 
chymotrypsin, elastase and carboxypeptidase (PTCEC gluten) was a gift from M. Bethune 
(Stanford University) and was prepared as follows: A solution of 15 mg/ml gluten was 
dissolved in 0.01 N HCL (pH ~2.1) and was incubated with 0.6 mg/ml pepsin (American 
Laboratories) for 60 min at 37ºC. The digest was adjusted to pH 6.5 with 50 mM sodium 
phosphate buffer and incubated with 0.375 mg/ml trypsin (Sigma), 0.375 mg/ml chymotrypsin 
(Sigma), 0.075 mg/ml elastase (Sigma) and 0.075 mg/ml carboxypeptidase A (Sigma) for 120 
min at 37ºC. The sample was heated to 95°C for 5 min to stop proteolysis followed by 
centrifugation and filtration of the supernatants. 
 
Validation of the enrichment procedure using synthetic peptides 
To test the specificity of the enrichment procedure, 20 μM of the synthetic peptides DQ2--I 
(QLQPFPQPQLPY) and DQ2--II (GIIQPQQPAQL) was separately mixed with 20 μM 5-
biotinamido-pentylamine (5-BP) in 10 μl of 100 mM Tris/HCl pH 7.4 supplemented with 2 mM 
CaCl2. Both samples were incubated with 0.1 μg/μl TG2 at 37C for 60 min before TG2 was 
inactivated by adding 1 μl iodoacetamide to a final concentration of 25 mM. A volume of 1 μl 
of each of the samples was added to 20 μl of 1 mg/ml PTCEC gluten digest. The sample was 
incubated with 200 μg Dynabeads M270 streptavidin (capacity: 200 pmol biotinylated 
peptides/1 mg beads) (Invitrogen Dynal AS, Norway) for 30 min in PBS/0.1% SDS followed 
by three washing steps each with 100 μl PBS/0.1% SDS and 100 μl 20% acetonitrile/water. 
For elution, beads were incubated with 15 μl 70% acetonitrile/2% formic acid/0.2 mM biotin 
for 30 min at 37ºC and the eluate was analyzed by MALDI-TOF mass spectrometry (Ultraflex 
II, Bruker Daltonics, Bremen, Germany). 
 In order to rank the peptides according to their level of transamidation, a sample containing 
20 μM of each of the peptide epitopes DQ2--II (PQPQLPYPQPQLPY), DQ2--II 
(GIIQPQQPAQL), DQ2--III (FPQQPQQPYPQQP) and DQ2--IV (FSQPQQQFPQPQ) was 
incubated with 0.1 g/l TG2 and 20 μM 5-BP in 20 μl 100 mM Tris/HCl pH 7.4 with 2 mM 
CaCl2 at 37C. Aliquots of 5 μl were removed after 1, 5 and 15 min incubation time and 1 μl 
iodoacetamide (final concentration 25 mM) was added to inactivate TG2. For enrichment, 1 μl 
of each of the samples was incubated with 150 μg Dynabeads M270 streptavidin for 30 min in 
PBS/0.1% SDS. Washing of the beads and elution of the enriched biotinylated peptides was 
performed as described above. MALDI-TOF spectra were acquired for the eluates of enriched 
transamidated peptides. 
 
Further, 30 μM of a chymotryptic digest of 2-gliadin was incubated with 0.1 g/l TG2 in 25 
μl 100 mM Tris/HCl pH 7.4 supplemented with 2 mM CaCl2 at 37C for 60 min and the 
reaction was terminated by adding 1 μl iodoacetamide to a final concentration of 25 mM. The 
sample was purified by C18 ZipTips (Millipore, Billerica, MA, USA), the eluate was vacuum-
dried, and the peptides were redissolved in 0.1% formic acid. Next, 300 fmol of the sample 
was analyzed by nano-LC coupled to a quadrupole-time-of-flight (Q-TOF) mass spectrometer 
(settings as described below). Similarly, 42 μM of a chymotryptic digest of 2-gliadin was 
incubated under identical conditions in the presence of 20 μM 5-BP. Transamidated peptides 
were enriched by incubating with 150 μg Dynabeads M270 streptavidin for 30 min in 
PBS/0.1% SDS followed by washing of the beads as described above. Enriched peptides 
were eluted by adding 10 μl of 70% acetonitrile/2% formic acid/0.2 mM biotin and incubating 
for 30 min at 37ºC. Finally, MALDI-TOF spectra were acquired. 
 
Treatment of a PTCEC gluten digest with TG2 and enrichment of transamidated gluten 
peptides 
A sample containing 1 mg/ml PTCEC gluten digest, 0.1 g/l TG2 and 200 pmol 5-BP in 100 
mM Tris/HCl pH 7.4 supplemented with 2 mM CaCl2 (total volume of 20 μl) was incubated at 
37C for 30 min. After inactivation of TG2 by adding iodoacetamide (final concentration of 25 
mM), the sample was incubated with 1 mg Dynabeads M270 streptavidin for 30 min in 
PBS/0.1% SDS and the beads were washed as described above. Enriched transamidated 
and biotinylated peptides were eluted from the beads by adding 25 μl of 70% acetonitrile/2% 
formic acid/0.2 mM biotin and incubating for 30 min at 37ºC. Finally, the eluate was vacuum-
dried. 
 
Analysis by nano-LC tandem mass spectrometry 
The transamidated peptides enriched from PTCEC gluten were analyzed either by a Q-TOF 
hybrid mass spectrometer (MicroTof-q, Bruker Daltonics, Bremen, Germany) or an Orbitrap 
mass spectrometer (LTQ Orbitrap XL, Thermo Scientific, Bremen, Germany), both coupled to 
a nano-LC system. For nano-LC-Q-TOF analysis, dried samples were dissolved in 8 μl 0.1% 
trifluoroacetic acid and a volume of 6 μl was injected into an Agilent 1100 series nano-LC 
system (Agilent Technologies, Palo Alto, CA). Peptides were separated on an analytical 
column (150 mm × 0.075 mm) packed with 100 Å C18 3.5 μm particles (G&T Septech AS, 
Norway). A linear gradient of 2-60% solvent B in 60 min was applied with a flow rate of 300 
nL/min (solvent A: 0.1 % acetic acid/water, solvent B: 0.1% acetic acid/acetonitrile). The Q-
TOF was operated in the data-dependent mode to automatically switch between MS and 
MS/MS acquisition. Collision energies were set between 30-50 eV depending on the charge 
state of the precursor ions. Data were acquired using microTOFControl v2.0 and processed 
using DataAnalysis v3.4. For nano-LC-Orbitrap analysis, the peptides were purified by C18 
ZipTips (Millipore, Billerica, MA, USA), vacuum-dried and redissolved in 10 μl of 1% formic 
acid, and then 3 μl were injected into an Ultimate 3000 nanoLC system (Dionex, Sunnyvale, 
CA, USA). For separation of peptides, an Acclaim PepMap 100 column (120 mm x 0.075 mm) 
packed with 100 Å C18 3 μm particles (Dionex) was used. A flow rate of 300 nL/min was 
employed with a solvent gradient of 7-35% B in 77 min and then from 35% to 50% B in 10 min 
(solvent A: 0.1% formic acid/water; solvent B: 0.1% formic acid/90% acetonitrile). The mass 
spectrometer was operated in the data-dependent mode to automatically switch between 
Orbitrap-MS and LTQ-MS/MS acquisition. Data were acquired using Xcalibur v2.5. 
 
 
Identification of enriched transamidated gluten peptides 
First, a database consisting of all known protein sequences derived from Triticum aestivum 
was built by extracting entries (n=4654) from the UniprotKB database (release 15.0) at the 
European Bioinformatics Institute (EBI) using the SRS server. The LC-MS/MS data were 
searched against this database using the Mascot search engine and Proteome Discoverer 
software version 1.0 (Thermo Fisher Scientific Inc., Waltham, MA). In Mascot the glutamine 
modification by 5-BP linkage (mass increase of 311.17 Da) was implemented and selected as 
variable modification together with deamidation of glutamine and aspargine and pyro-
glutamate formation. For analysis of LTQ-Orbitrap data, the mass tolerance was set as 10 
ppm for the precursor ion and 0.6 Da for the fragment ions, whereas for analysis of Q-TOF 
data the mass tolerance was set as 0.5 Da for the precursor ion and 0.2 Da for the fragments 
ions. All reported hits were in addition manually interpreted. If the glutamine residues targeted 
by TG2 could not be unambiguously assigned based on the MS/MS spectrum, also the 
established rules governing the targeting of glutamine residues by TG2 were considered.10, 11 
In a few cases, extracted ion chromatograms were generated to distinguish peptides that 
carry both transamidated and deamidated glutamine residues from peptides harboring only a 
transamidated glutamine residue. 
 
T cell assay 
The T-cell stimulatory capacity of the synthetic TG2-treated peptides 
SHQQQPFPQQPYPQQPYPS (peptide #25) and PHQPQQQVPQPQQPQQPF (peptide #19) 
were tested in proliferation assays together with a panel of synthetic epitope peptides using T-
cell lines derived from celiac disease patients as previously described.16 First, both peptides 
were incubated at 100 M with 0.1 g/l TG2 in 100 mM Tris/HCl pH 7.4 buffer supplemented 
with 2 mM CaCl2 for 120 min at 37C. Sixty thousand HLA-DQ2 homozygous EBV-
transformed B lymphoblastoid cells were irradiated (75 Gy) and incubated overnight with 
different concentrations of the TG2-treated peptides. On day 1, 40 000 cells from polyclonal 
T-cell lines generated from intestinal biopsies of celiac disease patients were added. One Ci 
3H-thymidine was added per well on day 3 and T-cell proliferation was measured as thymidine 
incorporation on day 4.  
Results 
Validation of the procedure to identify the best TG2 substrates  
Incubation of a PTCEC digest of whole wheat gluten with small amounts of the primary amine 
5-BP and TG2 will result in transamidation of a limited number of gluten peptides. In order to 
detect and identify these TG2 peptide substrates in such a heterogeneous peptide mixture, 
transamidated and hence biotinylated peptides were enriched using magnetic streptavidin 
beads (Fig. 1). First, we tested the specificity of the enrichment method for transamidated 
peptides. Two synthetic peptides known to be substrates for TG2, DQ2--I and DQ2--II, 
were each incubated with TG2 in the presence of 5-BP. Both samples were spiked into a 
PTCEC digest of gluten and streptavidin beads were added. Analysis by MALDI-TOF mass 
spectrometry before and after enrichment demonstrated a high specificity of the enrichment 
procedure as only the transamidated DQ2--I and DQ2--II peptides were detected after 
elution from streptavidin beads (Fig. 2). The transamidated peptides were not observed prior 
to enrichment. 
 
We next tested whether the deamidation and transamidation reactions catalyzed by TG2 
prefer the same gluten peptides. Previously we have shown that epitope peptides DQ2--II 
and DQ2--II undergo rapid deamidation by TG2, whereas epitope peptides DQ2--III and 
DQ2--IV are poorly deamidated [21]. Equal amounts of these four peptides were mixed with 
a limited amount of 5-BP and incubated with TG2 for different periods of time. The 
transamidated peptides were enriched from the samples and MALDI-TOF spectra were 
acquired. The relative signal intensities of the transamidated DQ2--II and DQ2--II epitope 
peptides increased much faster over time than those of the DQ2--III and DQ2--IV epitope 
peptides suggesting that the former are better substrates of TG2 (data not shown). This 
finding is consistent with previously reported data for deamidation of these four peptides [21]. 
Further, we tested which peptides were deamidated and transamidated from a heterogeneous 
mixture of peptides derived from digestion of a single recombinant 2-gliadin protein by 
chymotrypsin. For both reactions, the 33mer peptide (Table 1) and the peptide 
VRVPVPQLQPQNPSQQQPQEQVPL were identified as substrates. Thus we concluded that 
enrichment of gluten peptides by means of crosslinking with 5-BP can be used to provide 
information as to which peptides in a heterogeneous mixture are preferred also for the 
deamidation reaction. The method can also determine which glutamine residues within the 
preferred substrates are targeted by the enzyme. 
 
Identification of enriched gluten peptides by mass spectrometry 
In order to identify optimal TG2 gluten peptide substrates, a PTCEC digest of whole gluten 
was incubated with TG2 in the presence of limiting amounts of 5-BP for 30 minutes. After 
specific enrichment of transamidated gluten peptides by magnetic streptavidin beads, eluted 
peptides were identified by LC-MS/MS analysis and subsequent database searching (Fig. 1). 
Altogether, 31 different peptide sequences were identified from the enriched sample of 
transamidated gluten peptides (Table 2). The targeted glutamine (Q) residues in these 
peptides were typically in the QXP-motif which is in accordance with previous results 
regarding TG2 specificity [10,11]. Remarkably, the majority of the identified peptides contain 
complete or truncated versions of known gluten T-cell epitopes (Tables 1 and 2). Among the 
identified nine -gliadin derived peptides, five peptides harbor at least two of the DQ2--I, 
DQ2--II or DQ2--III epitopes. The DQ2--II epitope is present in all of the five peptides in 
one or two copies (peptides #1-5), while the DQ2--I and DQ2--III epitopes are present in 
peptides #3-5 and peptides #1-3, respectively. The -gliadin derived peptide #6 harbors an 
incomplete DQ2-20-epitope. The -gliadin derived 33mer peptide that is known to be a 
superior TG2 substrate was not identified. However, several isoforms (peptides #3 and #5) 
and truncated versions (peptides #1, #2, and #4) of this peptide were observed. The -gliadin 
derived peptides #7-9 do not harbor any known T-cell epitopes. Peptide #7 corresponds to 
the p31-44 “toxic” peptide previously reported [24]. 
 
Ten peptides derived from-gliadin were identified, and eight of these peptides contain parts 
of the DQ2--II epitope (peptides #10-17). Notably, these peptides share the same peptide 
core region but differ in their N- and C-terminal extensions. The DQ2--VIIb/DQ8--I epitope 
was present in one of the identified -derived peptides (peptide #18).  
 
Twelve identified peptides derive from glutenin proteins. The complete DQ2-restricted 
glutenin-17 epitope, Glt-17, was present in three of these peptides (peptides #21, #22 and 
#24) while two of the peptides (peptides #20 and #23) harbored truncated versions of the 
epitope. Interestingly, several of the other identified TG2 peptide substrates of glutenin 
proteins have sequences similar to known epitopes. 
 
Identification of two novel T-cell epitopes 
For some of the identified TG2 peptide substrates that do not contain any known T-cell 
epitopes, sequence motifs and targeting of Q residues suggested that they could bind to HLA-
DQ2.5. In an attempt to identify new T-cell epitopes, we therefore tested two of the peptides 
for recognition by gluten reactive, polyclonal T-cell lines generated from intestinal biopsies of 
HLA-DQ2.5-positive celiac disease patients. Peptide #19 (PHQPQQQVPQPQQPQQPF, 
predicted HLA-DQ2.5 binding register underlined, Q residue targeted by TG2 in bold) and 
peptide #25 (SHQQQPFPQQPYPQQPYPS, the two predicted overlapping HLA-DQ2.5 
binding registers are either underlined or in italics, Q residues targeted by TG2 in bold) were 
treated with TG2 and tested together with a panel of known gluten epitopes in a proliferation 
assay. Six of the seven gluten reactive, polyclonal T-cell lines tested did not recognize 
peptide #19 or peptide #25 (data not shown). However, the T-cell line BW.CD-E made a 
strong response to peptide #25 and a weaker response to peptide #19 in a TG2-dependent 
and dose-dependent fashion (Fig. 3). Except for epitopes DQ2--I and the DQ2-	-17mer 
peptide [25], none of the other peptides was recognized by this particular T-cell line. 
Interestingly, no T-cell response was observed for the DQ2--VI epitope which has a very 
similar sequence as peptide #25, indicating that there is no cross-reactivity between the new 
peptides and the DQ2--VI epitope in this T-cell line. 
 
Transamidation and deamidation of distinct glutamine residues within the same 
peptide 
Four -gliadin and one -gliadin derived TG2 peptide substrates were observed as derivatives 
carrying both a transamidated and a deamidated glutamine residue. For peptide #1 
(PQPQLPYPQPQLPYPQPQPF), transamidation and deamidation sites could be assigned to 
Q11 and Q4 (underlined), respectively. A transamidated and deamidated derivative was also 
observed for an elongated version of peptide #1. In this 25mer -gliadin peptide (peptide #3, 
QLQPFPQPQLPYPQPQLPYPQPQPF, targeted Q residues underlined), it could however not 
be unambiguously determined which of the two targeted glutamine residues (Q9 and Q16) 
was transamidated or deamidated. For peptide #8 (LQPQNPSQQQPQEQVPL), Q14 was 
found to be transamidated whereas Q9 was deamidated. These modifications were observed 
for the same glutamine residues in peptide #9 which represents an N-terminally extended 
derivative of peptide #8. The -gliadin derived peptide VQGQGIIQPQQPA (peptide #13) was 
identified to be transamidated at the Q4 residue and deamidated at the Q10 residue.  
 
Discussion 
In this study we have identified the preferred substrates of TG2 in proteolytic digests of whole 
wheat gluten. To simplify the identification we established an enrichment method which is 
based on the TG2-mediated transamidation reaction followed by sequence determination by 
mass spectrometry. We identified 31 different peptide substrates of TG2. Strikingly, the 
majority of these peptides harbor known gluten T-cell epitopes. 
 
To date, more than 15 HLA-DQ2.5 and HLA-DQ8-restricted gluten derived T-cell epitopes 
have been identified [12-19]. For the majority of HLA-DQ2.5-restricted gliadin epitopes, the 
kinetics of TG2-mediated deamidation was recently determined and large variations between 
the peptide epitopes were observed [21]. Interestingly, there seems to be a correlation 
between the level of deamidation of the different epitopes and how frequently the epitopes are 
recognized by T-cells of celiac disease patients. 
 
Peptide substrates of TG2 can be either transamidated or deamidated. Deamidated reaction 
products generated in the absence of primary amines can be directly detected by LC-MS in 
mixtures of low complexity, e.g. in a chymotryptic digest of a single recombinant gliadin 
protein. However, in our hands this approach was not feasible for the identification of the best 
substrates of TG2 when analyzing the PTCEC digest of whole gluten because of its extreme 
heterogeneity. Although the propensity for either of the two modifications may differ slightly for 
some peptide substrates, the substrate specificity for deamidation and transamidation overall 
appears very similar [23]. We confirmed this notion, as we found the same two peptides being 
substrates in the deamidation and transamidation reaction when testing a chymotryptic digest 
of a recombinant gliadin protein. Moreover, when testing substrate potency of four peptides 
for transamidation and deamidation, we observed the same rank order for the peptides in 
both reactions. We therefore decided to harness the transamidation reaction to identify the 
best peptide substrates in the complex peptide mixture of a PTCEC digest of whole gluten. By 
this approach, we were able to tremendously reduce the sample complexity by enriching for 
the TG2-modified peptides and thereby facilitating identification of individual peptides. 
 
The transamidation reaction in this highly competitive environment was performed in the 
presence of limited amounts of 5-BP and short incubation periods. It is striking that the 
majority of the identified transamidated peptides contained intact known T-cell epitopes or 
truncated versions thereof. Five of the nine identified -gliadin derived peptides carry more 
than one copy of either of the epitopes DQ2--I, DQ2--II, or DQ2--III, and eight of the ten 
identified -gliadin peptides harbor a part of the DQ2--II epitope. These epitopes showed also 
the highest deamidation rates in our recent study [21], and they constituted nearly half of the 
gluten-TG2 substrates we identified.  
 
The identified TG2 substrates that carry T-cell epitopes can be dichotomized according to 
whether they harbor complete or incomplete 9mer core binding regions. Interestingly, this 
classification correlates with the frequency by which the T-cell epitopes are recognized by T 
cells of celiac disease patients. T-cell epitopes that are frequently recognized by T cells of 
celiac disease patients (e.g. DQ2--I, DQ2--II/DQ2--III) were represented by their intact 
9mer sequences whereas the T-cell epitopes that are infrequently recognized (e.g. DQ2--II, 
gliadin-20, glutenin-17) were represented by partial 9mer sequences. This was particularly 
striking for the DQ2--II epitope which was never represented by a complete 9mer, but 
appeared in C-terminally truncated forms in 8 distinct peptides. In keeping with our results, 
Shan et al reported that the DQ2--II epitope was not among the most proteolytically stable 
fragments of a recombinant -gliadin protein [20]. These data underscore that proteolytic 
degradation is an important force in the selection of gluten T-cell epitopes in celiac disease. 
 
The sequences of some of the identified TG2 peptide substrates and the observed targeting 
by TG2 suggested that these peptides could contain new T-cell epitopes. Two of them, 
(peptide #19, PHQPQQQVPQPQQPQQPF, and peptide #25, SHQQQPFPQQPYPQQPYPS, 
suggested 9mer core region are underlined or in italic, Q residues targeted by TG2 are given 
in bold) were tested for recognition by polyclonal T-cell lines from HLA-DQ2.5-positive celiac 
disease patients. Interestingly, both peptides induced a dose-dependent T-cell response in 
one of the seven lines tested. The fact that this T-cell line did not cross-react with a highly 
similar known epitope, the DQ2--VI epitope, and otherwise displayed only weak to borderline 
responses toward two out of a large panel of known T-cell epitopes tested, strongly suggests 
that we have identified two novel gluten epitopes.  
 
Peptides #8 (LQPzNPSQQQPQEQVPL) and #9 (VPVPQLQPzNPSQQQPQEQVPL) 
(suggested 9mer core regions binding to HLA-DQ2.5 are underlined or in italic; Q residues 
targeted by TG2 in bold; z indicates Q or K) of the well-investigated 2-gliadin protein have 
also been reported as substrates for TG2 [26] and their sequences suggest that they bind to 
HLA-DQ2.5. Although peptides representative of peptide #9 have failed to stimulate any T-cell 
lines or T-cell clones tested so far by others [12,27], our results warrant further investigation 
into whether this indeed could be a T-cell epitope. Some of the remaining peptides which we 
identified (e.g. #28, #31) do most likely not harbor the binding motifs of HLA-DQ2.5 or HLA-
DQ8 and this probably explains why they are not T-cell epitopes in celiac disease. 
Notwithstanding these examples, we find it striking that the great majority of the preferred 
TG2 substrates in a complex gluten mixture contain known T-cell epitopes.  
 
Among the identified TG2 peptide substrates a few peptides were observed as transamidated 
and deamidated at the same time. These findings may have implications for the generation of 
TG2-specific autoantibodies in celiac disease whose appearance is strictly dependent on the 
dietary intake of gluten [28]. In a previously proposed hapten-carrier model, uptake of 
covalent complexes between TG2 and gluten peptides by TG2-specific B cells was suggested 
to result in activation of gluten-specific T-cells which subsequently provide help for the B cells 
to secrete antibodies [29]. In accordance with this hypothesis, cross-linking of gluten peptides 
to TG2 via generation of isopeptide bonds between glutamine residues in the peptide and 
lysine residues of TG2 has been described [30]. If those TG2-bound gluten peptides carry an 
additional deamidated glutamine residue in a T-cell epitope distant from the transamidation 
site, e.g. as observed for peptides #1 and #3, presentation of this epitope would only require 
cleavage of the peptide backbone by proteases present in the endocytic compartments while 
leaving the isopeptide bond intact. 
 
In a heterogeneous gluten digest, TG2 is not targeting all the different gluten peptides, but 
shows a clear preference for those which are found as T-cell epitopes in celiac disease 
patients. This finding argues for TG2 exerting a strong pressure in the selection of T-cell 
epitopes in celiac disease. Our data also demonstrate the important role of proteolysis in the 
selection of T-cell epitopes as the T-cell epitopes that are frequently recognized by T cells of 
celiac disease patients more often remain intact than the epitopes that are infrequently 
recognized. Together, the selective forces exerted by TG2 and gastrointestinal proteolysis are 
key factors to determine the repertoire of gluten epitopes in celiac disease.  
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Figure legends 
Figure 1: Schematic view of the established method to enrich and analyze TG2 peptide 
substrates. A PTCEC digest of wheat gluten was mixed with a small amount of 5-BP which 
served as a substrate for TG2 in a transamidation reaction. The transamidated, biotinylated 
peptides were enriched from the digest using magnetic streptavidin beads, eluted with an 
excess of biotin and analyzed by LC-MS/MS. Database searching was performed using a 
database made up of all entries of Triticum aestivum present in the Uniprot database. In 
addition, MS/MS spectra were manually inspected. 
 
Figure 2: Specific enrichment of transamidated peptides. A PTCEC digest of whole 
gluten was spiked with the transamidated DQ2--I and DQ2--II peptides. MALDI-TOF 
spectra before (upper panel) and after enrichment (lower panel) are shown. The inset shows 
the four signals obtained for each of the two enriched peptides that correspond to the 
transamidated peptide, its sodium adduct, its potassium adduct and the adduct with two 
sodium ions, respectively. All signals observed in the lower mass range (up to m/z 900) were 
derived from matrix clusters. 
 
Figure 3: Recognition of gluten peptides #19 and #25 by T-cell line BW.CD-E. 
The identified TG2 peptide substrates SHQQQPFPQQPYPQQPYPS (P#25) and 
PHQPQQQVPQPQQPQQPF (P#19) were tested together with a panel of synthetic epitope 
peptides for recognition by a T-cell line generated from a biopsy of a HLA-DQ2.5-positive 
celiac disease patient. The sequences of the other synthetic peptides tested were as follows: 
DQ2--I, QLQPFPQPELPY; DQ2--II, PQPELPYPQPQLPY; DQ2-33mer, 
LQLQPFPQPELPYPQPELPYPQPELPYPQPQPF; DQ2--I, pyroglu-PQQPQQSFPEQQRP; 
DQ2--II, GIIQPEQPAQL; DQ2--III, FPEQPEQPYPEQ; DQ2--IV, FSQPEQEFPQPQ; DQ2-
-VI, PEQPFPEQPEQ; DQ2--VIIa, TEQPEQPFPQP; DQ2--VIIb, FPQPEQEFPQPQ; DQ2--
III/DQ2--VI, LQPEQPFPEQPEQPYPEQPQ; DQ2-23mer, 
EQPFPEQPEQPYPEQPEQPFPQP; DQ2-	17mer, QPQQPFPQPEQPFPWQP. Note that 
peptide #25 and peptide #19 were tested at different concentrations. The DQ2-33mer 
peptide was tested at 2 μM while the other peptides were tested at 10 μM. Responses were 
measured in a proliferation assay by the incorporation of 3H-thymidine (counts per minute 
(CPM) x 103). The dashed line indicates two-fold background proliferation observed with 
medium only. Each antigen was tested in triplicates and error bars indicate the standard error 
of mean. The experiment was repeated twice. 
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